The genetics and biology of KRAS in lung cancer

Cancer Statistics, 2010

Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596 · see citing works

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · see citing works

ras oncogenes in human cancer: a review.

Bos, J. L. (1989) · PubMed · Cited by 5,061 · see citing works

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,869 · see citing works

The MAPK signaling cascade

Seger, R., & Krebs, E. G. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.9.7601337 · Cited by 3,631 · see citing works

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · see citing works

Somatic mutations affect key pathways in lung adenocarcinoma

Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · see citing works

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D. B., Tolcher, A. W., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,508 · see citing works

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · see citing works

Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer

Kim, C. F. B., Jackson, E. L., Woolfenden, A. E., Lawrence, S., Babar, I., Vogel, S., Crowley, D. G., Bronson, R. T., & Jacks, T. (2005) · Cell · doi:10.1016/j.cell.2005.03.032 · Cited by 2,196 · see citing works

Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-rasPreprint

Jackson, E. L., Willis, N. A., Mercer, K. L., Bronson, R. T., Crowley, D. G., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,877 · see citing works

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,818 · see citing works

Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

Winton, T. L., Livingston, R. B., Johnson, D. H., Rigas, J. R., Johnston, M., Butts, C. A., Cormier, Y. F., Goss, G., Inculet, R., Vallières, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810 · see citing works

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,614 · see citing works

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517 · see citing works

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,468 · see citing works

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S., Herbst, R. S., Ince, W. L., Janne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,453 · see citing works

The Concept of Synthetic Lethality in the Context of Anticancer Therapy

Kaelin, W. G. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1691 · Cited by 1,369 · see citing works

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J., Schrama, J. G., Erdkamp, F., Vos, A. H., van Groeningen, C. J., Sinnige, H. A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808268 · Cited by 1,330 · see citing works

Somatic activation of the K-ras oncogene causes early onset lung cancer in mice

Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · see citing works

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

Su, F., Virós, A., Milagre, C. S., Trunzer, K., Bollag, G. E., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038 · see citing works

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017 · see citing works

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841 · see citing works

A SNP in a let-7 microRNA Complementary Site in the KRAS 3′ Untranslated Region Increases Non–Small Cell Lung Cancer Risk

Chin, L. J., Ratner, E., Leng, S., Zhai, R., Nallur, S. V., Babar, I., Müller, R., Straka, E., Su, L., Burki, E. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2129 · Cited by 634 · see citing works

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

Mascaux, C., Iannino, N., Martin, B., Paesmans, M., Berghmans, T., Dusart, M., Haller, A., Lothaire, P., Meert, A.-P., Noël, S., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602258 · Cited by 604 · see citing works

Induction and apoptotic regression of lung adenocarcinomas by regulation of a <i>K-Ras</i> transgene in the presence and absence of tumor suppressor genes

Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes &amp; Development · doi:10.1101/gad.947701 · Cited by 582 · see citing works

The Differential Effects of Mutant <i>p53</i> Alleles on Advanced Murine Lung Cancer

Jackson, E. L., Olive, K. P., Tuveson, D. A., Bronson, R., Crowley, D., Brown, M., & Jacks, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2193 · Cited by 553 · see citing works

K-ras is an essential gene in the mouse with partial functional overlap with N-rasPreprint

Johnson, L., Greenbaum, D. C., Cichowski, K. M., Mercer, K. L., Murphy, E. A., Schmitt, E. S., Bronson, R. T., Umanoff, H., Edelmann, W., Kucherlapati, R., et al. (1997) · Genes & Development · doi:10.1101/gad.11.19.2468 · Cited by 540 · see citing works

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

Scholl, C., Fröhling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., Tamayo, P., Wadlow, R. C., Ramaswamy, S., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.017 · Cited by 539 · see citing works

Detection of p53 Gene Mutations in Human Brain Tumors by Single-strand Conformation Polymorphism Analysis of Polymerase Chain Reaction Products

Mashiyama, S., Kayama, T., Katakura, R., Yoshimoto, T., Murakami, Y., Sekiya, T., & Hayashi, K. (1991) · Springer eBooks · doi:10.1007/978-4-431-68150-2_41 · Cited by 538 · see citing works

Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets

Konstantinopoulos, P. A., Karamouzis, M. V., & Papavassiliou, A. G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2221 · Cited by 451 · see citing works

A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma

Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415 · see citing works

Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours

Malliri, A., van der Kammen, R. A., Clark, K., van der Valk, M., Michiels, F., & Collard, J. G. (2002) · Nature · doi:10.1038/nature00848 · Cited by 384 · see citing works

Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse.

You, M., Candrian, U., Maronpot, R. R., Stoner, G. D., & Anderson, M. W. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.9.3070 · Cited by 336 · see citing works

Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism

Lambert, J. M., Lambert, Q. T., Reuther, G. W., Malliri, A., Siderovski, D. P., Sondek, J., Collard, J. G., & Der, C. J. (2002) · Nature Cell Biology · doi:10.1038/ncb833 · Cited by 326 · see citing works

Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer

Tsao, M., Aviel‐Ronen, S., Ding, K., Lau, D., Liu, G., Sakurada, A., Whitehead, M., Zhu, C., Livingston, R. B., Johnson, D. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6953 · Cited by 326 · see citing works

Evidence for type II cells as cells of origin of K-Ras–induced distal lung adenocarcinoma

Xu, X., Rock, J. R., Lu, Y., Futtner, C. R., Schwab, B., Guinney, J., Hogan, B. L. M., & Onaitis, M. W. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112499109 · Cited by 304 · see citing works

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

Blasco, R. B., Francoz, S., Santamaría, D., Cañamero, M., Dubus, P., Charron, J., Baccarini, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.002 · Cited by 302 · see citing works

Wildtype Kras2 can inhibit lung carcinogenesis in mice

Zhang, Z., Wang, Y., Vikis, H. G., Johnson, L., Liu, G., Li, J., Anderson, M. W., Sills, R. C., Hong, H. L. T., Devereux, T. R., et al. (2001) · Nature Genetics · doi:10.1038/ng721 · Cited by 295 · see citing works

Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines

Mulshine, J. L. (1992) · Lung Cancer · doi:10.1016/0169-5002(92)90122-z · Cited by 294 · see citing works

Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.

Lobell, R. B., Omer, C. A., Abrams, M. T., Bhimnathwala, H., Brucker, M. J., Buser, C. A., Davide, J. P., DeSolms, S. J., Dinsmore, C. J., Ellis-Hutchings, M., et al. (2001) · PubMed · Cited by 239 · see citing works

Prognostic Significance of K-ras Codon 12 Mutations in Patients With Resected Stage I and II Non–Small-Cell Lung Cancer

Graziano, S. L., Gamble, G. P., Newman, N. B., Abbott, L. Z., Rooney, M., Mookherjee, S., Lamb, M., Kohman, L. J., & Poiesz, B. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.668 · Cited by 191 · see citing works

Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer

Garassino, M. C., Marabese, M., Rusconi, P., Rulli, E., Martelli, O., Farina, G., Scanni, A., & Broggini, M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq680 · Cited by 185 · see citing works

RalGDS is required for tumor formation in a model of skin carcinogenesis

González-Garcı́a, A., Pritchard, C. A., Paterson, H. F., Mavria, G., Stamp, G., & Marshall, C. J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.029 · Cited by 181 · see citing works

Detection of K-ras mutations in lung carcinomas: Relationship to prognosis

De Michele, M. A. A. (1996) · Lung Cancer · doi:10.1016/s0169-5002(96)80041-9 · Cited by 168 · see citing works

Ras caught in another affair: the exchange factors for Ral

Wolthuis, R. M. F., & Bos, J. L. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80016-1 · Cited by 156 · see citing works

Molecular footprints of human lung cancer progression

Yokota, J., & Kohno, T. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02203.x · Cited by 139 · see citing works

A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6

Gariboldi, M., Manenti, G., Canzian, F., Falvella, F. S., Radice, M. T., Pierotti, M. A., Porta, G. D., Binelli, G., & Dragani, T. A. (1993) · Nature Genetics · doi:10.1038/ng0293-132 · Cited by 130 · see citing works

Replacement of K‐Ras with H‐Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice

Potenza, N., Vecchione, C., Notte, A., Rienzo, A. D., Rosica, A., Bauer, L., Affuso, A., Felice, M. D., Russo, T., Poulet, R., et al. (2005) · EMBO Reports · doi:10.1038/sj.embor.7400397 · Cited by 126 · see citing works

Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.

Lobell, R. B., Liu, D., Buser, C. A., Davide, J. P., DePuy, E., Hamilton, K., Koblan, K. S., Lee, Y., Mosser, S. D., Motzel, S. L., et al. (2002) · PubMed · Cited by 121 · see citing works

Kras regulatory elements and exon 4A determine mutation specificity in lung cancer

To, M. D., Wong, C. E., Karnezis, A. N., Rosario, R. D., Lauro, R. D., & Balmain, A. (2008) · Nature Genetics · doi:10.1038/ng.211 · Cited by 117 · see citing works

While K-ras Is Essential for MouseDevelopment, Expression of the K-ras 4A Splice VariantIsDispensable

Plowman, S. J., Williamson, D. J., O’Sullivan, M. J., Doig, J., Ritchie, A., Harrison, D. J., Melton, D. W., Arends, M. J., Hooper, M., & Patek, C. E. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9245-9250.2003 · Cited by 104 · see citing works

Origin and prognostic value of circulating KRAS mutations in lung cancer patients

Gautschi, O. P., Huegli, B., Ziegler, A., Gugger, M., Heighway, J., Ratschiller, D., Mack, P. C., Gumerlock, P. H., Kung, H., Stahel, R. A., et al. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.03.008 · Cited by 95 · see citing works

Parental bias of Ki-ras oncogenes detected in lung tumors from mouse hybrids.

You, M., Wang, Y., Stoner, G. D., You, L., Maronpot, R. M., Reynolds, S. H., & Anderson, M. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.5804 · Cited by 93 · see citing works

High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase Inhibitors

Fiordalisi, J. J., Johnson, R. L., Weinbaum, C., Sakabe, K., Chen, Z., Casey, P. J., & Cox, A. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305733200 · Cited by 90 · see citing works

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

McCullough, A. J. (2013) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/j.ypat.2012.10.041 · Cited by 84 · see citing works

Developmentally-regulated expression of murine K-ras isoforms

Pells, S., Divjak, M., Romanowski, P., Impey, H., Hawkins, N. J., Clarke, A. R., Hooper, M. L., & Williamson, D. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201354 · Cited by 83 · see citing works

Detection of K-ras gene mutations in non-neoplastic lung tissue and lung cancers

Nelson, M. A., Wymer, J. A., & Clements, N. C. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04202-4 · Cited by 74 · see citing works

A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice

To, M. D., Pérez‐Losada, J., Mao, J., Hsu, J., Jacks, T., & Balmain, A. (2006) · Nature Genetics · doi:10.1038/ng1836 · Cited by 69 · see citing works

LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer

Li, J., Zhang, Z., Zunyan Dai, Y., Plass, C., Morris, Q., Wang, Y., Wiest, J. S., Anderson, M. W., & You, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206192 · Cited by 58 · see citing works

Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?

Camps, C., Sirera, R., Bremnes, R. M., Blasco, A., Sancho, E., Bayo, P., Safont, M. J., Sánchez, J. J., Tarón, M., & Rosell, R. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.06.007 · Cited by 53 · see citing works

Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler

Sasaki, H., Okuda, K., Kawano, O., Endo, K., Yukiue, H., Yokoyama, T., Yano, M., & Fujii, Y. (2007) · Oncology Reports · doi:10.3892/or.18.3.623 · Cited by 52 · see citing works

Comparison of gene expression and DNA copy number changes in a murine model of lung cancer

Sweet‐Cordero, A., Tseng, G. C., You, H., Douglass, M., Huey, B., Albertson, D., & Jacks, T. (2006) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20296 · Cited by 45 · see citing works

Mutagenesis of the K-ras protooncogene in mouse lung tumors induced by N-ethyl-N-nitrosourea or N-nitrosodiethylamine

You, M., Wang, Y., Lineen, A., Stoner, G. D., & Anderson, M. W. (1992) · Carcinogenesis · doi:10.1093/carcin/13.9.1583 · Cited by 45 · see citing works

Association of chromosome 12p genetic polymorphisms with lung adenocarcinoma risk and prognosis

Manenti, G. (1997) · Carcinogenesis · doi:10.1093/carcin/18.10.1917 · Cited by 35 · see citing works

ALTERNATIVE SPLICING OF THE K-RAS GENE IN MOUSE TISSUES AND CELL LINES

Wang, Y., You, M., & Wang, Y. (2001) · Experimental Lung Research · doi:10.1080/019021401300054028 · Cited by 33 · see citing works

Ki‐ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer

Gnanasampanthan, G., Elsaleh, H., McCaul, K. A., & Iacopetta, B. M. (2001) · The Journal of Pathology · doi:10.1002/path.990 · Cited by 31 · see citing works

Population-based mapping of pulmonary adenoma susceptibility 1 locus.

Dragani, T. A., Hirohashi, S., Juji, T., Kawajiri, K., Kihara, M., Ono‐Kihara, M., Manenti, G., Nomoto, T., Sugimura, H., Genka, K., et al. (2000) · PubMed · Cited by 30 · see citing works

Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis

Patek, C. E., Arends, M. J., Wallace, W. A., Luo, F., Hagan, S., Brownstein, D. G., Rose, L., Devenney, P. S., Walker, M., Plowman, S. J., et al. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.11.004 · Cited by 28 · see citing works

Progressive Genomic Instability in the FVB/KrasLA2 Mouse Model of Lung Cancer

To, M. D., Quigley, D. A., Mao, J., Rosario, R. D., Hsu, J., Hodgson, G., Jacks, T., & Balmain, A. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0219 · Cited by 21 · see citing works

Association of KRAS polymorphisms with risk for lung adenocarcinoma accompanied by atypical adenomatous hyperplasias

Kohno, T., Kunitoh, H., Suzuki, K., Yamamoto, S., Kuchiba, A., Matsuno, Y., Yanagitani, N., & Yokota, J. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn048 · Cited by 17 · see citing works

Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma

Francini, G., Petrioli, R., Gonnelli, S., Correale, P., Pozzessere, D., Marsili, S., Montagnani, A., Lucani, B., Rossi, S., Monaco, R. D., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6 · Cited by 15 · see citing works

Predisposition to lung tumorigenesis

Manenti, G., Nomoto, T., Gregorio, L. D., Gariboldi, M., Falvella, F. S., Nagao, M., & Dragani, T. A. (2000) · Toxicology Letters · doi:10.1016/s0378-4274(99)00232-5 · Cited by 15 · see citing works

A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6

Pierotti, M. A., Gariboldi, M., Manenti, G., Canzian, F., Palvella, F. S., Porta, G., Binelli, G., & Dragani, T. A. (1994) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(94)90251-8 · Cited by 6 · see citing works

Mutagenesis of the K-ras protooncogene in mouse lung tumors induced by N-ethyl-N-nitrosourea or n-nitrosodiethylamine

Lineen, A. M. (1993) · Lung Cancer · doi:10.1016/0169-5002(93)90348-2 · Cited by 3 · see citing works

The current state of the art and future trends in RAS-targeted cancer therapies

Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549 · see citing works

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

Gerber, D. E., Camidge, D. R., Morgensztern, D., Cetnar, J., Kelly, R. J., Ramalingam, S. S., Spigel, D. R., Jeong, W., Scaglioni, P. P., Zhang, S., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.033 · Cited by 167 · see citing works

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Galan-Cobo, A., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., et al. (2024) · Nature · doi:10.1038/s41586-024-07943-7 · Cited by 194 · see citing works

Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 137 · see citing works

YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting

Sardo, F. L., Strano, S., & Blandino, G. (2018) · Cancers · doi:10.3390/cancers10050137 · Cited by 120 · see citing works

Altered Lipid Metabolism in Blood Mononuclear Cells of Psoriatic Patients Indicates Differential Changes in Psoriasis Vulgaris and Psoriatic Arthritis

Wójcik, P., Biernacki, M., Wroński, A., Łuczaj, W., Waeg, G., Žarković, N., & Skrzydlewska, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174249 · Cited by 82 · see citing works

KRAS in NSCLC: State of the Art and Future Perspectives

Cascetta, P., Marinello, A., Lazzari, C., Gregorc, V., Planchard, D., Bianco, R., Normanno, N., & Morabito, A. (2022) · Cancers · doi:10.3390/cancers14215430 · Cited by 76 · see citing works

Smyd3-associated regulatory pathways in cancer

Giakountis, A., Moulos, P., Sarris, M. E., Hatzis, P., & Talianidis, I. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.08.008 · Cited by 74 · see citing works

Emerging Trends in the Application of Green Synthesized Biocompatible ZnO Nanoparticles for Translational Paradigm in Cancer Therapy

Naser, S. S., Ghosh, B., Simnani, F. Z., Singh, D., Choudhury, A., Nandi, A., Sinha, A., Jha, E., Panda, P. K., Suar, M., et al. (2023) · Journal of Nanotheranostics · doi:10.3390/jnt4030012 · Cited by 72 · see citing works

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas

Gu, M., Xu, T., & Chang, P. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211006950 · Cited by 61 · see citing works

Implications of KRAS mutations in acquired resistance to treatment in NSCLC

Re, M. D., Rofi, E., Restante, G., Crucitta, S., Arrigoni, E., Fogli, S., Maïo, M. D., Petrini, I., & Danesi, R. (2017) · Oncotarget · doi:10.18632/oncotarget.23553 · Cited by 62 · see citing works

High resolution crystal structure of a KRAS promoter G-quadruplex reveals a dimer with extensive poly-A π-stacking interactions for small-molecule recognition

Ou, A., Schmidberger, J. W., Wilson, K. A., Evans, C. W., Hargreaves, J. A., Grigg, M. C., O’Mara, M. L., Iyer, K. S., Bond, C. S., & Smith, N. M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa262 · Cited by 49 · see citing works

Selective targeting of point-mutated KRAS through artificial microRNAs

Acunzo, M., Romano, G., Nigita, G., Veneziano, D., Fattore, L., Laganà, A., Zanesi, N. A. O., Fadda, P., Fassan, M., Rizzotto, L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620562114 · Cited by 48 · see citing works

Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities

Daga, A., Ansari, A., Patel, S., Mirza, S., Rawal, R., & Umrania, V. V. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.10.4147 · Cited by 47 · see citing works

Quantitative structure–activity relationships analysis, homology modeling, docking and molecular dynamics studies of triterpenoid saponins as Kirsten rat sarcoma inhibitors

Stitou, M., Toufik, H., Bouachrıne, M., & Lamchouri, F. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1707122 · Cited by 44 · see citing works

Regulation of RhoB Gene Expression during Tumorigenesis and Aging Process and Its Potential Applications in These Processes

Gutierrez, E., Cahatol, I., Bailey, C., Lafargue, A. M., Zhang, N., Song, Y., Tian, H., Zhang, Y., Chan, R., Gu, K., et al. (2019) · Cancers · doi:10.3390/cancers11060818 · Cited by 43 · see citing works

Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy

Singh, S. S., Dahal, A., Shrestha, L., & Jois, S. D. S. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190222183219 · Cited by 42 · see citing works

Early KRAS oncogenic driver mutations in nonmucinous tissue of congenital pulmonary airway malformations as an indicator of potential malignant behavior

Hermelijn, S. M., Wolf, J. L., den Toom, T. D., Wijnen, R. M. H., Rottier, R. J., Schnater, J. M., & von der Thüsen, J. H. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.07.015 · Cited by 43 · see citing works

Studies in lung cancer cytokine proteomics: a review

Abolfathi, H., Sheikhpour, M., Shahraeini, S. S., Khatami, S., & Nojoumi, S. A. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1892491 · Cited by 41 · see citing works

Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease

Hartmann, O., Reissland, M., Maier, C. R., Fischer, T., Prieto‐Garcia, C., Baluapuri, A., Schwarz, J. D., Schmitz, W., Garrido‐Rodríguez, M., Pahor, N., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641618 · Cited by 38 · see citing works

Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I

Upadhya, A., Yadav, K. S., & Misra, A. R. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1825377 · Cited by 37 · see citing works

Oncogenic context shapes the fitness landscape of tumor suppression

Blair, L. M., Juan, J. M., Sebastian, L., Tran, V. B., Nie, W., Wall, G. D., Gerceker, M., Lai, I. K., Apilado, E. A., Grenot, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42156-y · Cited by 37 · see citing works

Structure, signaling and the drug discovery of the Ras oncogene protein

Han, C. W., Jeong, M. S., & Jang, S. B. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.7.062 · Cited by 35 · see citing works

Molecular Tumor Board Review and Improved Overall Survival in Non–Small-Cell Lung Cancer

Huang, B., Chen, Q., Allison, D. B., Khouli, R. H. E., Peh, K. H., Mobley, J., Anderson, A. M., Durbin, E. B., Goodin, D., Villano, J. L., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00210 · Cited by 35 · see citing works

Pan-cancer discovery of somatic mutations from RNA sequencing data

Tang, G., Liu, X., Cho, M., Li, Y., Tran, D.-H., & Wang, X. (2024) · Communications Biology · doi:10.1038/s42003-024-06326-y · Cited by 34 · see citing works

Molecular profiling of non-small cell lung cancer

Forsythe, M. L., Alwithenani, A., Bethune, D., Castonguay, M., Drucker, A., Flowerdew, G., French, D., Fris, J., Greer, W., Henteleff, H., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236580 · Cited by 35 · see citing works

The RAL signaling network: Cancer and beyond

Apken, L. H., & Oeckinghaus, A. (2020) · International review of cytology · doi:10.1016/bs.ircmb.2020.10.005 · Cited by 30 · see citing works

Novel Candidate Key Drivers in the Integrative Network of Genes, MicroRNAs, Methylations, and Copy Number Variations in Squamous Cell Lung Carcinoma

Huang, T., Jing, Y., & Cai, Y. (2015) · BioMed Research International · doi:10.1155/2015/358125 · Cited by 28 · see citing works

A CRISPR-Cas9 repressor for epigenetic silencing of KRAS

Liu, J., Sun, M., Cho, K. B., Gao, X., & Guo, B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105304 · Cited by 27 · see citing works

In vivo synergistic anti-tumor effect of lumefantrine combined with pH responsive behavior of nano calcium phosphate based lipid nanoparticles on lung cancer

Sethuraman, V., Janakiraman, K., Krishnaswami, V., Natesan, S., & Kandasamy, R. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105657 · Cited by 26 · see citing works

Quantitative CT imaging analysis to predict pathology features in patients with a congenital pulmonary airway malformation

Hermelijn, S. M., Mackenbach, M. J., van Horik, C., Ciet, P., Wolf, J. L., von der Thüsen, J. H., Wijnen, R. M. H., Tiddens, H. A. W. M., & Schnater, J. M. (2021) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2021.10.008 · Cited by 25 · see citing works

RAS‐targeted cancer therapy: Advances in drugging specific mutations

Liu, C., Ye, D., Yang, H., Chen, X., Su, Z., Li, X., Ding, M., & Liu, Y. (2023) · MedComm · doi:10.1002/mco2.285 · Cited by 24 · see citing works

Targeting the invasive phenotype of cisplatin-resistant Non-Small Cell Lung Cancer cells by a novel histone deacetylase inhibitor

Zuco, V., Cassinelli, G., Cossa, G., Gatti, L., Favini, E., Tortoreto, M., Cominetti, D., Scanziani, E., Castiglioni, V., Cincinelli, R., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.01.002 · Cited by 20 · see citing works

Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer

Leone, G. M., Candido, S., Lavoro, A., Vivarelli, S., Gattuso, G., Călina, D. C., Libra, M., & Falzone, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041252 · Cited by 19 · see citing works

Molecular markers as therapeutic targets in lung cancer

Tseng, H., & He, B. (2013) · 癌症：英文版 · doi:10.5732/cjc.013.10011 · Cited by 19 · see citing works

A multi-omics approach for identifying important pathways and genes in human cancer

Frost, H. R., & Amos, C. I. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2476-8 · Cited by 19 · see citing works

Non-Viral RNA Therapies for Non-Small Cell Lung Cancer and Their Corresponding Clinical Trials

Tiwade, P. B., Fung, V., VanKeulen‐Miller, R., Narasipura, E. A., Ma, Y., & Fenton, O. S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00871 · Cited by 18 · see citing works

STING Targeting in Lung Diseases

Rodrigues, D. D. M., Lacerda‐Queiroz, N., Couillin, I., & Riteau, N. (2022) · Cells · doi:10.3390/cells11213483 · Cited by 18 · see citing works

The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses

Ciccone, G., Ibba, M. L., Coppola, G., Catuogno, S., & Esposito, C. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076121 · Cited by 17 · see citing works

Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients

Yang, I. S., & Kim, S. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2011-y · Cited by 17 · see citing works

Recent Advances in Lung Cancer Therapy Based on Nanomaterials: A Review

Gholami, L., Ivari, J. R., Nasab, N. K., Oskuee, R. K., Sathyapalan, T., & Sahebkar, A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210810160901 · Cited by 17 · see citing works

Therapeutic Efficacy of Lactonic Sophorolipids: Nanoceria-Assisted Combination Therapy of NSCLC using HDAC and Hsp90 Inhibitors

Naz, S., Banerjee, T., Totsingan, F., Woody, K., Gross, R. A., & Santra, S. (2021) · Nanotheranostics · doi:10.7150/ntno.57675 · Cited by 16 · see citing works

Exploring cellular plasticity and resistance mechanisms in lung cancer: Innovations and emerging therapies

Jiang, C., Xie, S., Jia, K., Feng, G., Ren, X., & Wang, Y. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101179 · Cited by 15 · see citing works

Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma

Wen, S. W. C., Andersen, R. F., Petersen, L. M. S., Hager, H., Hilberg, O., Jakobsen, A. K. M., & Hansen, T. F. (2020) · Cancers · doi:10.3390/cancers12123728 · Cited by 15 · see citing works

IARS2 silencing induces non-small cell lung cancer cells proliferation inhibition, cell cycle arrest and promotes cell apoptosis

Yin, J. J., LIU, W., LI, R., Liu, J. L. J., ZHANG, Y., Tang, W., & WANG, K. (2015) · Neoplasma · doi:10.4149/neo_2016_008 · Cited by 14 · see citing works

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer

Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V. D., Rosovsky, R. P. G., Lilenbaum, R., Bastos, B. R., Huang, C. H., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.010 · Cited by 14 · see citing works

A call to action: molecular pathology in Brazil

da Cunha, I. W., Coudry, R. D. A., de Macêdo, M. P., de Assis, E. A. C. P., Stefani, S. D., & Soares, F. A. (2021) · Surgical and Experimental Pathology · doi:10.1186/s42047-021-00096-1 · Cited by 15 · see citing works

The Metabolic Landscape of Breast Cancer and Its Therapeutic Implications

Jiao, Z., Pan, Y., & Chen, F. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00645-2 · Cited by 13 · see citing works

Non-small cell lung cancer biomarkers and targeted therapy - two faces of the same coin fostered by nanotechnology

Mendes, R. G. P. R., Carreira, B., Baptista, P. V., & Fernandes, A. R. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1159914 · Cited by 13 · see citing works

Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies

Rashdan, S., & Gerber, D. E. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.57 · Cited by 13 · see citing works

Cisplatin and Pemetrexed Have Distinctive Growth-inhibitory Effects in Monotherapy and Combination Therapy on KRAS -dependent A549 Lung Cancer Cells

Mohiuddin, M., & Kasahara, K. (2021) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20282 · Cited by 11 · see citing works

Polyisoprenylated Cysteinyl Amide Inhibitors Deplete K-Ras and Induce Caspase-dependent Apoptosis in Lung Cancer Cells

Nkembo, A. T., Amissah, F., Ntantie, E., Poku, R. A., Salako, O. O., Ikpatt, O. F., & Lamango, N. S. (2019) · Current Cancer Drug Targets · doi:10.2174/1568009619666190325144636 · Cited by 11 · see citing works

CRISPR-mediated reversion of oncogenic KRAS mutation results in increased proliferation and reveals independent roles of Ras and mTORC2 in the migration of A549 lung cancer cells

Werner, A. N., Kumar, A. I., & Charest, P. G. (2023) · Molecular Biology of the Cell · doi:10.1091/mbc.e23-05-0152 · Cited by 10 · see citing works

Molecular mechanism of genetic, epigenetic, and metabolic alteration in lung cancer

Fatima, S., Kumar, V., & Kumar, D. (2025) · Medical Oncology · doi:10.1007/s12032-025-02608-5 · Cited by 11 · see citing works

Exhaled breath condensate efficacy to identify mutations in patients with lung cancer: A pilot study

Kazeminasab, S., Ghanbari, R., Emamalizadeh, B., Jouyban‐Gharamaleki, V., Taghizadieh, A., Jouyban, A., & Khoubnasabjafari, M. (2022) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2022.2046278 · Cited by 10 · see citing works

Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region

Tfayli, A., Fakhri, G. B., & Assaad, M. A. (2019) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_344_18 · Cited by 10 · see citing works

The Functional Effects of Key Driver KRAS Mutations on Gene Expression in Lung Cancer

Zhang, J., Hu, H., Xu, S., Jiang, H., Zhu, J., Qin, E., He, Z., & Chen, E. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00017 · Cited by 10 · see citing works

Construction and evaluation of a nomogram for predicting survival in patients with lung cancer

Ouyang, J., Hu, Z., Tong, J., Yang, Y., Wang, J., Chen, X., Luo, T., Yu, S., Wang, X., & Huang, S. (2022) · Aging · doi:10.18632/aging.203974 · Cited by 9 · see citing works

In Silico Screening of Mutated K-Ras Inhibitors from Malaysian Typhonium flagelliforme for Non-Small Cell Lung Cancer

Fatima, A., & Yee, H. F. (2014) · Advances in Bioinformatics · doi:10.1155/2014/431696 · Cited by 9 · see citing works

Untangling the KRAS mutated lung cancer subsets and its therapeutic implications

Kulshrestha, R., Kumar, P., Singh, A., Nupur, K., Spalgias, S., Mrigpuri, P., & Rajkumar (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00061-0 · Cited by 8 · see citing works

Mitochondrial VDAC1 Silencing in Urethane-Induced Lung Cancer Inhibits Tumor Growth and Alters Cancer Oncogenic Properties

Melnikov, N., Pittala, S., Shteinfer‐Kuzmine, A., & Shoshan‐Barmatz, V. (2024) · Cancers · doi:10.3390/cancers16172970 · Cited by 7 · see citing works

Joint analysis of sQTL and Hi-C reveals spatial proximity between sQTLs and target genes in cancer tissues

Eralp, B., & Sefer, E. (2025) · Scientific Reports · doi:10.1038/s41598-025-21746-4 · Cited by 7 · see citing works

Advances in siRNA-loaded liposomes for lung cancer: Challenges and future perspectives

Abla, K. K., Zahwi, M. K., El-Lakany, S. A., & Karam, M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145461 · Cited by 9 · see citing works

Dexamethasone activates c-Jun NH2-terminal kinase (JNK) which interacts with GR and protects it from ubiquitin-mediated degradation in NSCLC cells

Srivastava, S., Siddiqui, S. I., Chowdhury, S., & Trivedi, A. K. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.01.079 · Cited by 6 · see citing works

Adagrasib in KRYSTAL-12 has Broken the KRASG12C Enigma Code in Non-Small Cell Lung Carcinoma

Luo, F., & Arter, Z. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s490942 · Cited by 6 · see citing works

Targeting KRAS-G12C in lung cancer: The emerging role of PROTACs in overcoming resistance

Chidambaram, K., Rekha, A., Goyal, A., & Rana, M. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155954 · Cited by 5 · see citing works

Lung Metastases

Hayman, J., Naidoo, J., & Ettinger, D. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00057-8 · Cited by 5 · see citing works

Efficacy of siRNA-loaded nanoparticles in the treatment of K-RAS mutant lung cancerin vitro

Gencer, A., Baysal, İ., Nemutlu, E., Ciftci, S. Y., & Arıca, B. (2022) · Journal of Microencapsulation · doi:10.1080/02652048.2022.2061058 · Cited by 5 · see citing works

Circulating Nucleic Acids as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma

McGowan, R., Sally, Á., McCabe, A., Moran, B. M., & Finn, K. (2022) · Cancers · doi:10.3390/cancers14082027 · Cited by 5 · see citing works

Antioxidant defense gene expression associated with lung cancer pathology: implications for diagnostic and therapeutic targets

Chen, H., Xu, C.-W., Wang, W.-X., Huang, L., Li, X., Lan, G., Zhai, Z.-Q., Zhu, Y.-C., 杜开齐, & Chen, P. (2025) · Current Proteomics · doi:10.1016/j.curpro.2025.100033 · Cited by 4 · see citing works

Multi-omics integration in deciphering non-small cell lung cancer drug resistance: current status, challenges, and future prospects

Miao, J., Guan, W., Wang, J., Gong, H., Xie, Q., & Gao, Y. (2026) · Hereditas · doi:10.1186/s41065-025-00570-w · Cited by 4 · see citing works

Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes

Mangal, S., Debnath, A., Mazumder, R., Mazumder, A., Singh, R. K., Sanchitra, J., Jan, S., Pandey, P., Kumar, B., & Singh, A. K. (2024) · All Life · doi:10.1080/26895293.2024.2417192 · Cited by 4 · see citing works

Comprehensive Characterization of Stage IIIA Non-Small Cell Lung Carcinoma

Singh, N., Mishra, A., Sahu, D. K., Jain, M., Shyam, H., Tripathi, R. K., Shankar, P., Kumar, A., Alam, N., Jaiswal, R., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s279974 · Cited by 4 · see citing works

The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures

Ferrara, M. G., Stefani, A., Pilotto, S., Carbone, C., Vita, E., Salvatore, M. D., D’Argento, E., Sparagna, I., Monaca, F., Valente, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.792385 · Cited by 4 · see citing works

The Absence of Mutations in the Exon 2 KRAS Gene in Several Ethnic Groups in North Sumatra May Not the Main Factor for Lung Cancer

Soeroso, N. N., Ananda, F. R., Pradana, A., Tarigan, S. P., Syahruddin, E., & Noor, D. R. (2021) · Acta Informatica Medica · doi:10.5455/aim.2021.29.108-112 · Cited by 4 · see citing works

Detection of aberrant locomotor activity in a mouse model of lung cancer via home cage monitoring

Tomanelli, M., Guffanti, F., Vargiu, G., Micotti, E., Rigamonti, M., Tumiatti, F., Caiola, E., Marabese, M., & Broggini, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1504938 · Cited by 3 · see citing works

MicroRNAs and lung cancer: overview of essential pathways and somatic mutations in cancer progression

Tirpe, A., Nutu, A. M., Busuioc, C. I., Pop, O. L., & Berindan‐Neagoe, I. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1677471 · Cited by 3 · see citing works

Evolution of computational techniques against various KRAS mutants in search for therapeutic drugs: a review article

Mehmood, A., Hakami, M. A., Ogaly, H. A., Subramaniyan, V., Khalid, A., & Wadood, A. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04767-8 · Cited by 3 · see citing works

Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer

Karachaliou, A., Kotteas, E. A., Fiste, O., & Syrigos, K. (2024) · Cancers · doi:10.3390/cancers16081447 · Cited by 3 · see citing works

High‐Frequency Mutations in TP53 , AXIN1 , CTNNB1 , and KRAS , and Polymorphisms in JAK1 Genes Among Mongolian HCC Patients

Bold, N., Buyanbat, K., Ariya, E., Myagmar, N., Batbayar, G., Sandag, Z., Damdinbazar, D., Oyunbat, N., Boldbaatar, T., Ankhbayar, E., et al. (2025) · Cancer Reports · doi:10.1002/cnr2.70227 · Cited by 3 · see citing works

The Endeavours in RAS Inhibition - the Past, Present, and Future

Hussain, J., Kirubakaran, S., & Ravi, S. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200903163044 · Cited by 3 · see citing works

Ferroptosis and Radiotherapy in Lung Cancer

Patel, P. C., & Galvan, E. (2025) · Cells · doi:10.3390/cells14231927 · Cited by 2 · see citing works

A New Theory of Chemically Induced Tumorigenesis

Bogen, K. T. (2016) · Advances in molecular toxicology · doi:10.1016/b978-0-12-804700-2.00001-5 · Cited by 2 · see citing works

A Model for Lung Cancer Prediction

Khan, F., Pradhan, K., & Sinha, D. (2021) · International Conference on Advances in Computing, Communication Control and Networking (ICAC3N) · doi:10.1109/icac3n53548.2021.9725462 · Cited by 2 · see citing works

KiSS-1 Modulation by Epigenetic Agents Improves the Cisplatin Sensitivity of Lung Cancer Cells

Beretta, G. L., ALAMPI, D. M., Corno, C., Carenini, N., Corna, E., & Perego, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25095048 · Cited by 2 · see citing works

Theranostics in Lung Neuroendocrine Tumors

Dev, I. D., Puranik, A. D., Trikalinos, N. A., Girod, B., Kim, H., & Prasad, V. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.02.010 · Cited by 2 · see citing works

Biomarkers in Pulmonary Carcinomas

Gündoğdu, B., Gürel, D., & Ulukuş, E. Ç. (2022) · Springer eBooks · doi:10.1007/978-3-030-84432-5_5 · Cited by 2 · see citing works

Intracranial metastases

Halima, A., Mayo, Z. S., Jung, E. W., Ellithi, M., Chao, S. T., Murphy, E. S., & Suh, J. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822835-7.00045-7 · Cited by 2 · see citing works

Computational study for the identification of phytochemical from Acacia hydaspica as potent inhibitor for addressing KRAS-related non-small cell lung cancer: Perspectives on ligand-based drug discovery

Rabbi, M. R., & Morshed, M. R. (2025) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100080 · Cited by 1 · see citing works

Artificial intelligence, omics, and biomarkers: Redefining lung cancer early detection

Nizam, A., Shireen, N., Hasan, M. R., Singh, S., Farooqui, M. R., Naithani, D., & Farooqi, H. (2026) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2026.101312 · Cited by 1 · see citing works

Primary tumor type prediction based on US nationwide genomic profiling data in 13,522 patients

Huang, Y., Pfeiffer, S. M., & Zhang, Q. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.07.036 · Cited by 1 · see citing works

Lung Cancer Prediction using Machine Learning

Khan, F., Pradhan, K., & Sinha, D. (2021) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-1204 · Cited by 1 · see citing works

Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patientsPreprint

Moon, I., LoPiccolo, J., Baca, S. C., Sholl, L. M., Kehl, K. L., Hassett, M. J., Liu, D., Schrag, D., & Gusev, A. (2022) · medRxiv · doi:10.1101/2022.12.22.22283696 · Cited by 1 · see citing works

Inhibition of lung adenocarcinoma cells by insulin‐like growth factor‐ I receptor and K irsten rat sarcoma mutations: A mutation analysis with antisense oligodeoxynucleotide

Li, S., Zhao, L., Zhang, J., Zou, Z., & Du, P. (2014) · Thoracic Cancer · doi:10.1111/1759-7714.12176

DISCRIMINANT SCORE (D SCORE) A MODEL TO PREDICT LUNG CANCER BASED ON THE EXPRESSION STUDY OF PANEL OF GENES AND MICRORNAS IN THE PLASMA.

MB ChB (Baghdad), M. P. (. U. A. A. B. O. S. P. A. P. M. P., & Aljebori., H. (2018) · International Journal of Advanced Research · doi:10.21474/ijar01/6377

Unravelling Lung Cancer Heterogeneity and Associated Therapeutic Responses using in vivo and ex vivo Model Systems

Nagaraj, A. S. (2018) · Työväentutkimus Vuosikirja

KRAS-Mutated Lung Cancer

Basu, A., & Nieva, J. J. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_10

Role of N-WASP in cell proliferation : implication for organ development and cancer

Verma, A. (2020) · doi:10.32657/10356/143422

In-Silico Analysis of The Correlation Between PD-L1 and Pro-Inflammatory Type Interleukins and The Distribution of Their Potential Primary Sources in KRAS-Mutated Non-Small Cell Lung Carcinoma

Ünver, N. (2021) · Acta Medica · doi:10.32552/2021.actamedica.559

Investigational Chemotherapy and Novel Pharmacokinetics for the Treatment of Cancers of the CNS

Shah, N. (2018) · doi:10.33915/etd.7250

Defining the role of different KRAS effectors in the initiation and progression of lung cancer

Vandal, G. (2013) · eScholarship@McGill (McGill) · doi:10.82308/25940

KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations

O’Hagan, R. C., & Heyer, J. (2011) · Genes & Cancer · doi:10.1177/1947601911408080 · Cited by 38 · see citing works

Overview of KRAS‐Driven Genetically Engineered Mouse Models of Non‐Small Cell Lung Cancer

Sheridan, C., & Downward, J. (2015) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1435s70 · Cited by 14 · see citing works

Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets

Drosten, M., & Barbacid, M. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1360-5 · Cited by 12 · see citing works

RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies

Fang, B. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv090 · Cited by 35 · see citing works